Table 4 Effect of low-dose ASA and clopidogrel on the risk of UGIB
Cases (n = 152) n (%) | Controls (n = 1,000) n (%) | Odds ratioa (95 % CI) | P value | |
|---|---|---|---|---|
ASA | ||||
Non-use | 29 (19.1) | 186 (18.6) | 1 (−) | |
Current use | 107 (70.4) | 753 (75.3) | 1.31 (0.76–2.27) | 0.33 |
Duration | ||||
< 1 month | 8 (5.3) | 32 (3.2) | 0.92 (0.29–2.91) | 0.89 |
1–12 months | 38 (25.0) | 191 (19.1) | 1.26 (0.62–2.57) | 0.53 |
≥ 1 year | 61 (40.1) | 530 (53.0) | 1.39 (0.72–2.67) | 0.33 |
Dose | ||||
75 mg/day | 98 (64.5) | 653 (65.3) | 1.40 (0.80–2.43) | 0.23 |
150 mg/day | 6 (3.9) | 85 (8.5) | 0.53 (0.18–1.59) | 0.26 |
300 mg/day | 3 (2.0) | 15 (1.5) | 2.47 (0.60–10.24) | 0.21 |
Recent use | 10 (6.6) | 24 (2.4) | 4.33 (1.61–11.66) | <0.01 |
Past use | 6 (3.9) | 37 (3.7) | 0.85 (0.30–2.44) | 0.76 |
Clopidogrel | ||||
Non-use | 96 (63.2) | 765 (76.5) | 1 (−) | |
Current use | 48 (31.6) | 164 (16.4) | 2.17 (1.35–3.49) | <0.01 |
Duration | ||||
< 1 month | 10 (6.6) | 11 (1.1) | 5.76 (1.82–18.27) | <0.01 |
1–12 months | 25 (16.4) | 73 (7.3) | 2.14 (1.10–4.18) | 0.03 |
≥ 1 year | 13 (8.6) | 80 (8.0) | 1.80 (0.85–3.80) | 0.12 |
Dose | ||||
75 mg/day | 46 (30.3) | 154 (15.4) | 2.22 (1.38–3.59) | <0.01 |
≥ 150 mg/day | 2 (1.3) | 10 (1.0) | 1.19 (0.22–6.31) | 0.84 |
Recent use | 2 (1.3) | 13 (1.3) | 1.12 (0.22–5.64) | 0.89 |
Past use | 6 (3.9) | 58 (5.8) | 0.64 (0.25–1.68) | 0.37 |
Dual antiplatelet therapy | ||||
Non-use of both ASA and clopidogrel | 18 (11.8) | 119 (11.9) | 1 (−) | |
Current use of both ASA and clopidogrel | 36 (23.7) | 100 (10.0) | 2.42 (1.09–5.36) | 0.03 |
Current ASA use and non-current clopidogrel use | 71 (46.7) | 653 (65.3) | 0.91 (0.46–1.80) | 0.78 |
Current clopidogrel use and non-current ASA use | 12 (7.9) | 64 (6.4) | 1.29 (0.52–3.20) | 0.58 |